Prothena Corp Public (PRTA) Liabilities and Shareholders Equity (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Liabilities and Shareholders Equity of $349.9 million in Q1 2026, up 7.07% quarter-over-quarter from $326.8 million in Q4 2025, and down 29.36% on a YoY basis from $495.3 million in Q1 2025.
Prothena Corp Public (PRTA) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Prothena Corp Public's Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $349.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 29.36% year-over-year to $349.9 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 37.44% YoY), while the FY2025 annual figure was $326.8 million, down 40.27% from the prior year.
- Liabilities and Shareholders Equity was $349.9 million for Q1 2026 at Prothena Corp Public, up from $326.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $758.0 million in Q4 2022 to a low of $326.8 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $569.6 million across 5 years, with a median of $581.4 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 53.12% in 2022, then tumbled 40.76% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $758.0 million in 2022, then slipped by 8.13% to $696.4 million in 2023, then slipped by 21.44% to $547.1 million in 2024, then sank by 40.27% to $326.8 million in 2025, then advanced by 7.07% to $349.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $349.9 million (Q1 2026), $326.8 million (Q4 2025), and $352.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 349.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 349.89 Mn |
| Dec 31, 2025 | 326.80 Mn |
| Sep 30, 2025 | 352.63 Mn |
| Jun 30, 2025 | 399.07 Mn |
| Mar 31, 2025 | 495.34 Mn |
| Dec 31, 2024 | 547.11 Mn |
| Sep 30, 2024 | 595.25 Mn |
| Jun 30, 2024 | 645.57 Mn |
| Mar 31, 2024 | 623.19 Mn |
| Dec 31, 2023 | 696.38 Mn |
| Sep 30, 2023 | 746.92 Mn |
| Jun 30, 2023 | 720.65 Mn |
| Mar 31, 2023 | 741.59 Mn |
| Dec 31, 2022 | 758.04 Mn |
| Sep 30, 2022 | 554.44 Mn |
| Jun 30, 2022 | 549.59 Mn |
| Mar 31, 2022 | 581.41 Mn |
| Dec 31, 2021 | 609.37 Mn |
| Sep 30, 2021 | 632.70 Mn |
| Jun 30, 2021 | 436.38 Mn |